Aspirina - pain and inflammation - 8 coated tablets 500 mg

Product Description

Bayer - Aspirin Pain and Inflammation 500mg coated tablets

The new Aspirin has been formulated for faster action on PAIN and INFLAMMATION. Thanks to the innovative MICROACTIVE technology, its rapid-dissolving tablet releases micro-sized particles that dissolve in a few minutes, allowing for faster absorption of the active ingredient. Hence the advantage of an action twice as effective. Faster against pain than a classic 500g Aspirin tablet.

Available in packs of 20 and 8 tablets›
In coated tablets›
With the practical blister you can take it with you when you need it

Indications

Symptomatic treatment of fever and/or mild to moderate pain, such as headache, flu syndrome, toothache, muscle pain.

Contraindications

Hypersensitivity to acetylsalicylic acid or other salicylates, or to any of the excipients, history of asthma or hypersensitivity reactions (e.g. urticaria, angioedema, severe rhinitis, shock) induced by the administration of salicylates or substances with a similar action, in particular nonsteroidal anti-inflammatory drugs (NSAIDs), ulcer Active peptic ulcer, haemorrhagic diathesis, severe renal insufficiency, severe hepatic insufficiency, uncontrolled severe cardiac insufficiency, concomitant administration of methotrexate in doses greater than 20 mg per week, for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses, concomitant administration of oral anticoagulants for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses and in patients with a history of gastroduodenal ulcers, from the beginning of the sixth month of pregnancy (beyond the twenty-fourth week of amenorrhea), children and adolescents under 16 years of age.

Dosage

Adults and adolescents (from 16 years of age and above): 1 to 2 tablets for each dose to be repeated as needed after a minimum period of 4 hours. The maximum daily dose should not exceed 6 tablets. Elderly (65 years and older): 1 tablet for each dose, repeated as needed after a minimum of 4 hours. The maximum daily dose should not exceed 4 tablets. Acetylsalicylic acid should not be taken for more than 3 days (in case of fever) or 3-4 days (in case of pain) unless otherwise indicated by your doctor. Paediatric population: Acetylsalicylic acid should not be used in children and adolescents under 16 years of age without a medical prescription. Acetylsalicylic acid should be used with caution in patients with abnormal liver or kidney function or with circulatory problems. Method of administration: For oral use. The tablets should be taken with an adequate amount of fluids.

Warnings

In case of combination with other medicinal products, to avoid any risk of overdose, check that acetylsalicylic acid is not in the composition of these other medicinal products. Reye's syndrome, a very rare and potentially fatal condition, has been described in children with symptoms of viral infections (particularly chickenpox and influenza) with or without aspirin use. Therefore, aspirin should be administered to children with these conditions only after medical advice and when other measures have proven ineffective. In case of persistent vomiting, altered consciousness, or abnormal behavior, aspirin treatment should be discontinued. If high-dose analgesics are administered for a prolonged period, headache attacks should not be treated with higher doses. Regular use of analgesics, especially combinations of analgesics, can cause permanent kidney damage, with the risk of renal failure. In some severe forms of G6PD deficiency, high doses of aspirin can cause hemolysis. In cases of G6PD deficiency, aspirin should be administered under medical supervision. Treatment monitoring should be intensified in the following cases: in patients with a history of gastric or duodenal ulcer, gastrointestinal bleeding, or gastritis; in patients with renal insufficiency; in patients with hepatic insufficiency; in patients with asthma: the occurrence of an asthma attack, in some patients, may be related to an allergy to nonsteroidal anti-inflammatory drugs or acetylsalicylic acid; in such cases, this medicine is contraindicated; in patients with metrorrhagia or menorrhagia (risk of increased volume and duration of menstrual cycles). Gastrointestinal bleeding or ulcers/perforations may occur at any time during treatment, without necessarily having any warning signs or history in the patient. The relative risk increases in the elderly, in those with low body weight, and in patients receiving anticoagulants or platelet aggregation inhibitors. In the event of gastrointestinal bleeding, treatment should be discontinued immediately. Given the inhibitory effect of acetylsalicylic acid on platelet aggregation, which occurs even at very low doses and persists for several days, the patient should be aware of the risk of haemorrhage in the event of surgical procedures, even minor ones (e.g., tooth extraction). In analgesic or antipyretic doses, acetylsalicylic acid inhibits uric acid excretion; in doses used in rheumatology (anti-inflammatory doses), acetylsalicylic acid has a uricosuric effect. The use of this medicine is not recommended during breastfeeding. The administration of acetylsalicylic acid is not recommended with: oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid (>=500 mg per administration and/or <3 g per day) and in patients without a history of gastroduodenal ulcers. Other nonsteroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory doses of acetylsalicylic acid (>= 1 g per administration and/or >= 3 g per day) or with analgesic or antipyretic doses of acetylsalicylic acid (>= 500 mg per administration and/or < 3 g per day). Low molecular weight heparins (and related molecules) and unfractionated heparins at therapeutic doses or in elderly patients (> 65 years) regardless of the heparin dose, and for anti-inflammatory doses of acetylsalicylic acid (>= 1g per administration and/or >= 3g per day) or with analgesic or antipyretic doses of acetylsalicylic acid (>= 500 mg per administration and/or <3g per day), clopidogrel (beyond the approved indications for this combination in patients with acute coronary disease), ticlopidine, uricosurics, glucocorticoids (except hydrocortisone replacement therapy) for anti-inflammatory doses of acetylsalicylic acid (>= 1g per administration and/or >= 3g per day), pemetrexed in patients with mildly to severely impaired renal function. moderate (creatinine clearance between 45 ml/min and 80 ml/min), anagrelide: increased risk of haemorrhage and decreased antithrombotic effect.

Interactions

In the following text, the following definitions apply: anti-inflammatory doses of acetylsalicylic acid are defined as ">= 1g per administration and/or >= 3g per day", analgesic or antipyretic doses of acetylsalicylic acid are defined as ">=500 mg per administration and/or < 3 g per day". Several substances give rise to interactions due to their platelet aggregation inhibitor properties: abciximab, acetylsalicylic acid, cilostazol, clopidogrel, epoprostenol, eptifibatide, iloprost, iloprost trometamol, prasugrel, ticlopidine, tirofiban, ticagrelor. The risk of bleeding increases with the use of multiple platelet aggregation inhibitors, as well as with their use in combination with heparin or related molecules, oral anticoagulants, or other thrombolytics, and must be assessed through constant clinical monitoring. >>Contraindicated combinations. Methotrexate in doses greater than 20 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: Increased toxicity of methotrexate, particularly haematological toxicity (due to reduced renal elimination of methotrexate caused by acetylsalicylic acid). Oral anticoagulants with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid and in patients with a history of gastroduodenal ulcers: Increased risk of haemorrhage. >>Combinations not recommended. Oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid and in patients without a history of gastroduodenal ulcers: Increased risk of haemorrhage. Other nonsteroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: Increased risk of gastrointestinal ulcers and bleeding. Low molecular weight heparins (and related molecules) and unfractionated heparins at curative doses, or in elderly patients (>=65 years) regardless of the heparin dose, and for anti-inflammatory doses of acetylsalicylic acid or analgesic or antipyretic doses of acetylsalicylic acid: Increased risk of bleeding (inhibition of platelet aggregation and aggression of the gastroduodenal mucosa by acetylsalicylic acid). Another anti-inflammatory drug, or another analgesic or antipyretic, should be used. Clopidogrel (outside the approved indication for this combination in patients with acute coronary syndrome): Increased risk of bleeding. If concomitant administration cannot be avoided, clinical monitoring is recommended. Ticlopidine: Increased risk of haemorrhage. If concomitant administration cannot be avoided, clinical monitoring is recommended. Uricosurics (benzbromarone, probenecid): Reduced uricosuric effect due to competition for uric acid elimination in the renal tubules. Glucocorticoids (excluding hydrocortisone replacement therapy) at anti-inflammatory doses of acetylsalicylic acid: Increased risk of haemorrhage. Pemetrexed in patients with mild to moderate renal impairment (creatinine clearance between 45 ml/min and 80 ml/min) increases the risk of pemetrexed toxicity (due to decreased renal elimination of pemetrexed caused by acetylsalicylic acid) at anti-inflammatory doses of acetylsalicylic acid. Anagrelide: Increased risk of haemorrhage and decreased antithrombotic effect. If concomitant administration cannot be avoided, clinical monitoring is recommended. Combinations requiring precautions for use. Diuretics, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor antagonists, with anti-inflammatory doses of acetylsalicylic acid or with analgesic or antipyretic doses of acetylsalicylic acid: Acute renal failure may occur in dehydrated patients due to a reduction in glomerular filtration rate caused by decreased renal prostaglandin synthesis. Furthermore, the antihypertensive effect may be reduced. Ensure that the patient is hydrated and that renal function is monitored at the start of treatment. Methotrexate at doses <= 20 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: Increased toxicity of methotrexate, particularly hematological toxicity (due to reduced renal elimination of methotrexate caused by acetylsalicylic acid). Blood counts should be monitored weekly during the first weeks of concomitant administration. Patients with reduced renal function (even mild) and elderly patients should be closely monitored. Clopidogrel (in the approved indication for this combination in patients with acute coronary syndrome): Increased risk of bleeding. Clinical monitoring is recommended. Topical gastrointestinal treatments, antacids, and activated charcoal: Increased renal excretion of acetylsalicylic acid due to urine alkalinization. It is recommended that antacids and topical gastrointestinal treatments be administered at least two hours after acetylsalicylic acid. Pemetrexed in patients with normal renal function: increased risk of pemetrexed toxicity (due to decreased renal elimination of pemetrexed caused by acetylsalicylic acid) with anti-inflammatory doses of acetylsalicylic acid. Renal function should be monitored. Combinations that must be taken into consideration. Glucocorticoids (excluding hydrocortisone replacement therapy) for analgesic and antipyretic doses of acetylsalicylic acid: increased risk of haemorrhage. Deferasirox: with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased risk of gastrointestinal ulcers and haemorrhage. Low molecular weight heparins (and related molecules) and unfractionated heparins in preventive doses in patients <65 years of age: by influencing haemostasis at various levels, concomitant administration increases the risk of haemorrhage. Therefore, in such patients, the coadministration of heparins (or related molecules) in preventive doses, and acetylsalicylic acid at any dose, should be considered in combination with clinical and laboratory monitoring as needed. Thrombolytics: increased risk of haemorrhage. Selective Serotonin Reuptake Inhibitors: increased risk of haemorrhage.

Undesirable Effects

Frequencies: not known (cannot be estimated from the available data). Blood and lymphatic system disorders: bleeding and bleeding tendency (epistaxis, bleeding gums, purpura, etc.) with increased bleeding time. The risk of bleeding may persist for 4-8 days after stopping aspirin. It may increase the risk of bleeding during surgery. Intracranial and gastrointestinal bleeding may also occur. Immune system disorders: hypersensitivity reactions, anaphylactic reactions, asthma, angioedema. Nervous system disorders: headache, dizziness, sensation of hearing loss, tinnitus, usually indicating overdose. Intracranial hemorrhage. Gastrointestinal disorders: abdominal pain. Occult or overt gastrointestinal bleeding (hematemesis, melena, etc.) resulting in iron deficiency anemia. The risk of bleeding is dose-related. Gastric ulcers and perforations. Hepatobiliary disorders: elevated liver enzymes, usually reversible upon discontinuation of treatment, liver damage, primarily hepatocellular in nature. Skin and subcutaneous tissue disorders: urticaria, rash. General disorders: Reye's syndrome. It is important to report adverse reactions after authorization. This allows for continued monitoring of the benefit-risk balance of the medicinal product.

Pregnancy

Inhibition of prostaglandin synthesis may have adverse effects on the course of pregnancy and/or embryo-fetal development. Data from epidemiological studies suggest an increased risk of spontaneous abortion, cardiac malformations, and gastroschisis following the use of prostaglandin synthesis inhibitors in early pregnancy. The risk appears to increase with dose and duration of treatment. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. Additionally, an increased incidence of various malformations, including cardiovascular, has been reported in animals administered a prostaglandin synthesis inhibitor during the organogenetic period of gestation. Unless absolutely essential, acetylsalicylic acid should not be administered during the first 24 weeks of amenorrhea. If acetylsalicylic acid is administered to women attempting to conceive or who are pregnant during the first 24 weeks of amenorrhea, the dose should be as low as possible and the duration of treatment as short as possible. Beyond the 24th week of amenorrhea, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligohydramnios. In the final phase of pregnancy, the mother and newborn may experience: prolonged bleeding time, due to the inhibition of platelet aggregation, which can occur even at very low doses of aspirin; inhibition of uterine contractions, which causes delayed or prolonged labor. Therefore, aspirin is contraindicated after the fifth month of pregnancy (beyond 24 weeks of amenorrhea). Acetylsalicylic acid passes into breast milk; therefore, the use of aspirin is not recommended during breastfeeding. There is some evidence that drugs that inhibit cyclooxygenase/prostaglandin synthesis may impair female fertility due to an effect on ovulation. This effect is reversible upon discontinuation of treatment.